Advanced Hyaluronic Acid Technologies

Patent-Pending Hyaluronic Acid Technology for Joint Applications

Studio Bioscience is advancing ARC, a proprietary hyaluronic acid platform designed to support differentiated intra-articular injectable products for joint health, osteoarthritis, and related orthopedic applications.

Led by Dr. Polyak, Studio Bioscience combines deep HA formulation expertise with patented and patent-pending technologies across joint, aesthetic, and ophthalmic applications.

Primary Licensing Opportunity

Patent-pending HA technology for intra-articular joint applications.

Relevant for companies active in viscosupplementation, osteoarthritis therapies, orthopedic injectables, medical devices, sports medicine, and sterile injectable manufacturing.

The ARC Platform

A Proprietary HA Platform for Differentiated Formulations

ARC is Studio Bioscience’s proprietary hyaluronic acid technology platform.

The platform is designed to support controlled HA structuring and application-specific formulation development.

ARC may enable partners to develop differentiated HA-based products with tailored rheological, structural, and functional properties.

Potential applications include:

Intra-articular joint injections
Aesthetic injectables
HA-based ophthalmic formulations
Specialized medical formulations

Proven HA Expertise Across Multiple Applications

Dr. Polyak has extensive experience developing HA-based technologies across aesthetic, ophthalmic, medical device, and injectable applications.

His work includes HA-based aesthetic injectable technologies licensed for selected markets, as well as HA-based ophthalmic formulation development for a partner company.

This track record supports Studio Bioscience’s ability to adapt HA expertise across multiple biomedical use cases and collaborate with partners from formulation development through commercialization-oriented programs.

Additional HA Partnership Opportunities

In addition to the primary joint application opportunity, Studio Bioscience is open to selected partnership discussions in adjacent HA fields.

Aesthetic Injectables

HA-based aesthetic injectable technologies have been licensed for the United States and Latin America. Geographic rights for Europe and Canada remain available, subject to existing agreements and field restrictions.

Ophthalmic Manufacturing

Dr. Polyak has contributed to HA-based ophthalmic formulation development for a partner company. Studio Bioscience is interested in identifying North American GMP manufacturing partners for HA-based ophthalmic products.

Why Partner With Studio Bioscience

patent-pending innovation for intra-articular joint applications
proprietary HA technology and know-how
deep formulation expertise across HA-based products
experience supporting industry product development
flexible licensing and co-development structures
access to technical documentation under NDA

Interested in HA Technology Licensing or Development Partnerships?

Studio Bioscience is actively engaging qualified partners for licensing, co-development, and manufacturing discussions.